4
Changes in Ownership
Enliven Therapeutics, Inc. Filed Acc 0001415889-24-019202
CHIEF SCIENTIFIC OFFICER sold 12,000 shares at $22.89 ($274,736)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 2024-07-01 | Sale 10b5-1 | −12,000 | $22.89 | $274,736 | 1,105,035 | I: show line 1 in the form |
| Open-market sales · 12,000 sh · avg $22.89 · $274,736 | |||||||
Loading xslF345X05/form4-07032024_080732.xml…